Form SC 13G/A May 11, 2017
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934 (Amendment No. 1)*
Aratana Therapeutics, Inc. (Name of Issuer)
Common Stock, \$0.001 par value (Title of Class of Securities)
03874P101 (CUSIP Number)
May 9, 2017 (Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect t

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No 03874P101

NAME OF

1. REPORTING

PERSONS

I.R.S.

IDENTIFICATION

NOS. OF

ABOVE

PERSONS

(ENTITIES

ONLY)

Broadfin

Capital,

LLC

CHECK THE

APPROPRIATE

BOX IF A

². MEMBER OF A

GROUP (SEE

INSTRUCTIONS)

(a) [_]

(b) [X]

, SEC USE

ONLY

CITIZENSHIP

4. OR PLACE

. OF

ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY EACH

REPORTING

PERSON WITH

SOLE

5. VOTING

POWER

```
SHARED
6. VOTING
  POWER
  4,455,442
  SOLE
7. DISPOSITIVE
  POWER
  0
  SHARED
8. DISPOSITIVE
  POWER
  4,455,442
  AGGREGATE
  AMOUNT
  BENEFICIALLY
  OWNED BY EACH
  REPORTING
  PERSON
  4,455,442
  CHECK
  BOX IF
  THE
  AGGREGATE
  AMOUNT
10.IN ROW (9)
  EXCLUDES
  CERTAIN
  SHARES
  (SEE
  INSTRUCTIONS)
              [\_]
  PERCENT
  OF CLASS
  REPRESENTED
11.<sub>BY</sub>
  AMOUNT
  IN ROW (9)
  10.59%
```

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO, IA

CU_{i}	SIP 3874P101
No.)38/4P101

1.	NAME OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE
	PERSONS (ENTITIES ONLY)

Broadfin Healthcare Master Fund, Ltd.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

- (a) [_]
- (b) [X]

- 3. SEC USE ONLY
- 4. CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER

0

6. SHARED VOTING POWER

4,455,442

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

4,455,442

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,455,442

CHECK BOX IF THE AGGREGATE AMOUNT
10.IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

10.59%

12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

CUSIP No 03874P101

NAME OF

1. REPORTING

PERSONS

I.R.S.

IDENTIFICATION

NOS. OF

ABOVE

PERSONS

(ENTITIES

ONLY)

Kevin

Kotler

CHECK THE

APPROPRIATE

BOX IF A

. MEMBER OF A

GROUP (SEE

INSTRUCTIONS)

(a) [_]

(b) [X]

3. SEC USE ONLY

CITIZENSHIP

OR PLACE

4. OF

ORGANIZATION

United

States of

America

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY EACH

REPORTING

PERSON WITH

SOLE

5. VOTING

POWER

0

SHARED

6. VOTING **POWER**

4,455,442

SOLE

7. DISPOSITIVE **POWER**

0

SHARED

8. DISPOSITIVE **POWER**

4,455,442

AGGREGATE

AMOUNT

BENEFICIALLY

OWNED BY EACH

REPORTING

PERSON

4,455,442

CHECK

BOX IF

THE

AGGREGATE

AMOUNT

10.IN ROW (9)

EXCLUDES

CERTAIN

SHARES

(SEE

INSTRUCTIONS)

[_]

PERCENT

OF CLASS

REPRESENTED 11. BY

AMOUNT

IN ROW (9)

10.59%

TYPE OF REPORTING 12.PERSON (SEE INSTRUCTIONS)

IN, HC

CUSIP No 03874P101

Item 1. (a). Name of Issuer:

Aratana Therapeutics, Inc.

(b). Address of Issuer's Principal Executive Offices:

11400 Tomahawk Creek Parkway, Suite 340 Leawood, Kansas 66211

Item 2. (a). Name of Person Filing:

Broadfin Capital, LLC Broadfin Healthcare Master Fund, Ltd. Kevin Kotler

(b). Address of Principal Business Office, or if None, Residence:

Broadfin Capital, LLC 300 Park Avenue, 25th Floor New York, New York 10022 United States of America

Broadfin Healthcare Master Fund, Ltd. 20 Genesis Close Ansbacher House, Second Floor P.O. Box 1344 Grand Cayman KY1-1108 Cayman Islands

Kevin Kotler c/o Broadfin Capital, LLC 300 Park Avenue, 25th Floor New York, New York 10022 United States of America

(c) Citizenship:

Broadfin Capital, LLC – Delaware Broadfin Healthcare Master Fund, Ltd. – Cayman Islands Kevin Kotler – United States of America

(d). Title of Class of Securities:

Common Stock, \$0.001 par value

(e). CUSIP Number:

03874P101

Item 3.	This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a	
(a) [_] Bro	oker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).	
(b)[_]Bai	nk as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).	
(c) [_] Ins	urance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).	
(d)[_]Inv	restment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).	
(e) [_] An	investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);	
(f) [_] An	employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);	
(g)[_]A p	parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);	
(h)[_]A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);		
(i) [_] A c	church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the estment Company Act of 1940 (15 U.S.C. 80a-3);	
(j) [_]Gro	oup, in accordance with $s.240.13d-1(b)(1)(ii)(J)$.	

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

```
Broadfin Capital, LLC – 4,455,442
Broadfin Healthcare Master Fund, Ltd. – 4,455,442
Kevin Kotler – 4,455,442
```

(b) Percent of class:

```
Broadfin Capital, LLC – 10.59%
Broadfin Healthcare Master Fund, Ltd. – 10.59%
Kevin Kotler – 10.59%
```

- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote

```
Broadfin Capital, LLC – 0
Broadfin Healthcare Master Fund, Ltd. – 0
Kevin Kotler – 0
```

(ii) Shared power to vote or to direct the vote

```
Broadfin Capital, LLC – 4,455,442
Broadfin Healthcare Master Fund, Ltd. – 4,455,442
Kevin Kotler – 4,455,442
```

(iii) Sole power to dispose or to direct the disposition of

```
Broadfin Capital, LLC – 0
Broadfin Healthcare Master Fund, Ltd. – 0
Kevin Kotler – 0
```

(iv) Shared power to dispose or to direct the disposition of

```
Broadfin Capital, LLC – 4,455,442
Broadfin Healthcare Master Fund, Ltd. – 4,455,442
Kevin Kotler – 4,455,442
```

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].

N/A

Item 6 Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent 7. Holding Company.

If a parent holding company or control person has filed this schedule, pursuant to Rule § 240.13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

See Exhibit A attached hereto.

Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

N/A

Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

May 11, 2017 (Date)

BROADFIN CAPITAL, LLC* By: /s/ Kevin Kotler (Signature)

Kevin Kotler, Managing Member (Name/Title)

May 11, 2017 (Date)

BROADFIN HEALTHCARE MASTER FUND, LTD. By: /s/ Kevin Kotler (Signature)

Kevin Kotler, Director (Name/Title)

May 11, 2017 (Date)

By: /s/ Kevin Kotler* (Signature)

Kevin Kotler (Name/Title)

*The Reporting Persons disclaim beneficial ownership in the shares reported herein except to the extent of their pecuniary interest therein.

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of

such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

AGREEMENT

The undersigned agree that this Schedule 13G dated May 11, 2017 relating to the Common Stock, \$0.001 par value of Aratana Therapeutics, Inc. shall be filed on behalf of the undersigned.

May 11, 2017 (Date)

BROADFIN CAPITAL, LLC By: /s/ Kevin Kotler (Signature)

Kevin Kotler, Managing Member (Name/Title)

May 11, 2017 (Date)

BROADFIN HEALTHCARE MASTER FUND, LTD. By: /s/ Kevin Kotler (Signature)

Kevin Kotler, Director (Name/Title)

May 11, 2017 (Date)

By: /s/ Kevin Kotler (Signature)

Kevin Kotler (Name/Title)

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

EXHIBIT A

Broadfin Capital, LLC is the relevant entity for which Kevin Kotler may be considered a control person.